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Strategies to limit damage and improve repair after myocardial infarct remain a major therapeutic goal in cardiology. Our previous
studies have shown that constitutive expression of a locally acting insulin-like growth factor-1 Ea (IGF-1Ea) propeptide promotes
functional restoration after cardiac injury associated with decreased scar formation. In the current study, we investigated the
underlying molecular and cellular mechanisms behind the enhanced functional recovery. We observed improved cardiac function
inmice overexpressing cardiac-specific IGF-1Ea as early as day 7 aftermyocardial infarction. Analysis of gene transcription revealed
that supplemental IGF-1Ea regulated expression of key metalloproteinases (MMP-2 and MMP-9), their inhibitors (TIMP-1 and
TIMP-2), and collagen types (Col 1𝛼1 and Col 1𝛼3) in the first week after injury. Infiltration of inflammatory cells, which direct the
remodelling process, was also altered; in particular there was a notable reduction in inflammatory Ly6C+ monocytes at day 3 and
an increase in anti-inflammatory CD206+ macrophages at day 7. Taken together, these results indicate that the IGF-1Ea transgene
shifts the balance of innate immune cell populations early after infarction, favouring a reduction in inflammatory myeloid cells.
This correlates with reduced extracellular matrix remodelling and changes in collagen composition that may confer enhanced scar
elasticity and improved cardiac function.
1. Introduction
Cardiovascular diseases (CVD) are the major cause of death
globally, with myocardial infarction (MI) being one of
the main causes of mortality [1]. After MI, the damaged
myocardium releases inflammatory signals that trigger a cas-
cade of cellular processes in order to repair damaged tissue,
leading to the formation of scar tissue and left ventricular
(LV) dysfunction [2, 3].
Our laboratory has characterised the therapeutic proper-
ties of the insulin-like growth factor-1 Ea (IGF-1Ea) propep-
tide during wound healing/regeneration and pathological
inflammation.The IGF-1 gene is encoded in 70 kb of genomic
DNA distributed over six exons and five introns [4, 5].
Use of alternative start codons generates proteins with N-
terminal variability while different exon use at the 3󸀠 end
generates multiple C-terminal extension-peptides, termed E-
peptides. The most predominant is a 35-amino-acid-long E-
peptide, termed Ea, alternating with a far less abundant E-
peptide termed Eb or mechanogrowth factor (MGF) [6, 7].
TheE-peptides control local IGF-1 bioavailability by adhering
strongly to the extracellular matrix (ECM), retaining the
propeptides locally and preventing their release into the cir-
culation [8]. Expressed as a cardiomyocyte-specific transgene
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or delivered locally to the mouse heart, IGF-1Ea improves
functional recovery after cardiac injury [9, 10]; however the
underlying mechanisms are not fully understood.
Tissue restructuring after infarction involves the break-
down of the ECM by proteolytic enzymes, mainly the matrix
metalloproteinases (MMP) MMP-2 and MMP-9, balanced
by interaction with tissue inhibitors of metalloproteinases
(TIMPs) [11]. Initially a temporary matrix is formed, pri-
marily composed of collagen type III (Col I𝛼3), providing a
scaffold for replacement cells and structural integrity to the
heart, thereby reducing the risk of LVdilation and rupture [12,
13]. This is later replaced by collagen type I (Col I𝛼1) which
will constitute the permanent ECM [14]. Col I𝛼1 confers
tensile strength and resistance to stretch and deformation,
while Col I𝛼3 confers compliance. Their balance determines
cardiac tissue stiffness with increased Col I𝛼3 to Col I𝛼1 ratio
generating a more resilient left ventricle [13, 14].
Innate immune cells recruited to the injuredmyocardium
from the blood include neutrophils, monocytes, macro-
phages, and dendritic cells [15–17].Theyplay a prominent role
in remodelling, producing the MMPs that break down the
matrix, synthesising new ECM components, and activating
fibroblasts to myofibroblasts which will later in the inflam-
matory process be the main producers of matrix proteins
[14]. The tissue microenvironment at a given time after
MI influences the recruitment of immune cells as well as
their phenotypic and functional properties. This is especially
relevant for the macrophage population which undergoes a
time-dependent shift between inflammatory and reparative
functions [3, 18]. At early time points after injury, themajority
of macrophages produce inflammatory cytokines and reac-
tive oxygen species including interleukin- (IL-) 1𝛽, IL-12,
MMP-9, and nitric oxide. These are termed inflammatory
or M1-polarised macrophages, which express high levels
of Ly6C and function to recruit more inflammatory cells
and phagocytose cellular debris and produce growth factors
[12]. As the inflammation progresses, reparativemacrophages
accumulate in the infarct area. In contrast to the inflamma-
torymacrophages, these cells, many of which express CD206,
are involved in the suppression of inflammation due to high
production of IL-10 and TGF-𝛽 [3, 19] and assist in the
progression from inflammation to repair.
They also perform reparative roles promoting cell growth,
angiogenesis, and remodelling of the ECM. Additionally,
differentmonocyte populations can be distinguished by Ly6C
in themouse andmay preferentially give rise to inflammatory
versus reparative macrophages.
We have previously shown that IGF-1Ea and its mature
circulating form IGF-1 can modulate immune responses and
suppress pathological inflammation by inducing regulatory
cytokines and immune cell types [20, 21]. In the heart, IGF-
1Ea increased expression of IL-10 after cardiotoxin injury and
decreased levels of IL-1𝛽 suggesting that a shift in immune
cell populations may also occur in the heart [9]. In the
present study, we investigated whether there was a difference
in the immune cell dynamics after MI in transgenic IGF-
1Ea hearts and whether this had a carry-on effect on tissue
remodelling.
2. Materials and Methods
2.1. Cardiac Injury Model. Myocardial infarction by perma-
nent left coronary artery occlusion was induced in wild-
type (WT) and 𝛼MHC.IGF-1Ea male mice which were 8
to 12 weeks old. Surgeries were performed under mechan-
ical ventilation with 1–2.5% isofluorane. The chest cav-
ity was opened through the left fourth intercostal space.
The heart was exposed and the left coronary artery was
ligated using an 8.0mm non-absorbable suture (Ethicon-
Johnson & Johnson, USA) below the left atrium to produce
an ischemic region of 20–30% of the left ventricle area. The
chest cavity and skin were sutured with 6.0mm silk sutures
(Ethicon-Johnson & Johnson, USA). Analgesic treatment
with buprenorphine (0.3mg/kg, s.c.) was provided before
and after surgery. They were housed in individually venti-
lated cages in temperature-controlled facilities on a 12-hour
light/dark cycle on standard diet. All mouse procedures were
approved by the Imperial College London Ethical Committee
and were in accordance with national and international
regulations (UK Home Office Project license 70/7589).
2.2. Echocardiography. Echocardiographicmeasurements were
taken using a high-frequency ultrasound system Vevo 770
(VisualSonics, Inc., Canada) with a 30MHz linear transducer
and recorded images were analyzed by using the Vevo 770
workstation software. Mice were anesthetised with 1-2%
isofluorane, and the anesthetic flow rate was adjusted to
maintain heart rate of approximately 450 ± 50 beats per
minute. Furthermore, warmed ultrasound gel and a heating
platform were used to maintain body temperature at 37 ±
0.5∘C to minimise variation between mice. This analysis was
performed at basal level, 1, 3, 4, 7, and 28 days after MI to
evaluate left ventricle cardiac function, chamber dimensions,
and infarct size.
2.3. Masson’s Trichrome Staining. Samples were fixed in
paraformaldehyde (4% in PBS) for 48 h, washed in PBS,
dehydrated, and embedded in paraffin wax. Five-micron-
thick sections were stained with Celestine Blue for 5 minutes,
washed in tap water, and then incubated in haematoxylin
for 5 minutes. Slides were then incubated with Acid Fuchsin
for 5 minutes, rinsed in distilled water, incubated in phos-
phomolybdic acid (1%), and then rinsed in distilled water
before staining with Methyl Blue for 2-3 minutes. Slides were
dehydrated in ascending concentrations of ethanol, cleared in
xylene, and mounted in DPX (VWR, UK).
2.4. Cell Isolation. To analyse neutrophils, monocytes,
macrophages, and dendritic cells, a single cell suspension
was prepared from hearts before or at various time points
after MI (days 1, 3, 5, 7, and 28 after operation). The hearts
were mechanically dissociated using surgical scissors and
subsequently treated with a 1x Hank’s Balanced Salt Solution
(HBSS) (Invitrogen, USA), enzymatic dissociation buffer
containing 0.1mg/mL Liberase TH Research Grade (Roche
Diagnostics, UK), 50 𝜇g/mL of DNaseI (Roche Diagnostics,
UK), 10mM HEPES (Invitrogen, USA), and 30mM Taurine
(Sigma, UK) for 4 cycles of 10min at 37∘C. After each 10min
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incubation cycle, the cells were collected and filtered using
a 70 𝜇m cell strainer (BD Pharmingen, USA) and an equal
volume of ice cold 1xHBSS containing 10mMHEPES, 30mM
Taurine (Sigma, UK), and 20% Fetal Bovine Serum (FBS)
(GE Healthcare, USA) was added to the enzyme dissociation
buffer. The cells were pelleted at 320 g for 7min at 4∘C and
washed with the 1x HBSSmedia solution containing 20% FBS
as described above. Under these isolation conditions, adult
cardiomyocytes are predominately lysed, as the enzymatic
dissociation buffer is toxic to these large, fragile cells [22]. An
aliquot of the cell suspension was used to quantify the cell
concentration/mL using a Beckman Coulter Vi-Cell XR cell
counter (Beckman Coulter, High Wycombe, UK).
2.5. Flow Cytometry and Cell Sorting. Isolated cells were
incubated in a 1x Dulbecco’s Modified Eagle Medium
(DMEM) solution (Gibco, Life Technologies, UK) containing
2% FBS and 10mM HEPES for 30min, on ice, in the
dark, with the following primary antibodies: CD11b-PE (BD
Biosciences; catalogue 553311), F4-80-Biotin (eBioscience;
catalogue 13-4801-85), CD45-APC-Cy7 (BioLegend; cata-
logue 103116), CD206-PerCP-Cy5.5 (BioLegend; catalogue
141716), Ly6C-APC (eBioscience; catalogue 17-5932-82), and
Ly6G-AlexaFluor700 (BioLegend; catalogue 127622). Sam-
ples stainedwith biotin-labelled primary antibodywere incu-
bated with a streptavidin-PE-Cy7 (eBioscience; catalogue 25-
4317-82) secondary antibody for 30min, on ice, in the dark,
with the 1x DMEM media solution as mentioned above. The
samples were washed and resuspended in fresh 1x DMEM
media solution with 1.5 𝜇M Sytox Blue (Invitrogen. USA)
dead cell stain and refiltered using 5mL, 35 𝜇m filter cap
tubes (BD Falcon) just prior to sample acquisition. Flow
cytometric cell sorting was performed using a BD FAC-
SAriaI cell sorter (BD Biosciences, Oxford, UK) equipped
with a 355 nm UV laser, a 405 nm Violet laser, a 488 nm
Blue laser, a 561 nm Yellow-Green laser, and a 640 nm Red
laser. The antibody cocktail fluorescence minus one (FMO)
controls were used as gating controls for analyses to distin-
guish positive from negative fluorescence signal (see Sup-
plementary 4–6 in Supplementary Material available online
at http://dx.doi.org/10.1155/2015/484357). Total leukocytes
(CD45+), neutrophils (CD45+, CD11b+, F4/80−, CD11c−,
and Ly6G+), and monocytes (CD45+, CD11b+, CD11c−,
Ly6G−, and F4/80−) were analysed. Monocytes were further
classified as Ly6Chigh and Ly6Clow monocytes. Macrophages
were defined as CD45+, CD11b+, CD11c−, Ly6G−, and
F4/80+ and further characterised on the basis of Ly6C and
CD206 expression (i.e., Ly6Chigh/CD206low (inflammatory
macrophages) and Ly6Clow/CD206high (reparative macro-
phages)). Dendritic cells were defined as CD45+, CD11b+,
F4/80−, CD11c+, and Ly6G−. Flow Jo software (version 9. 8.5)
(Tree Star, Ashland, OR) was used for analysis.
2.6. RNA Isolation and cDNAGeneration. Mouse heart tissue
was harvested and flushed with cold PBS. Samples from the
infarct and remote (non-infarct) myocardium were placed
in a 1.5mL tube and homogenised in TRIzol (Invitrogen,
USA) reagent using a rotor-stator homogeniser (Polytron PT
2500 E). Total RNA was isolated according to the TRIzol
manufacturer’s instructions. RNA was pelleted, air-dried,
and resuspended in DNase/RNase free water and the yield
quantified using Nanodrop (Thermo Scientific, USA) at
260 nm. One microgram of RNA was reverse-transcribed
into cDNA using the Quantitect Reverse Transcription Kit
(QIAGEN, Crawley, UK).
2.7. Quantitative Real-Time PCR. Following cDNA synthesis,
quantitative RT-PCR using TaqMan probes (Invitrogen.
USA) was performed on an ABI 7900HT Sequence
Detection System (Applied Biosystems, Carlsbad, CA,
USA). The probes used were IGF-1Ea (Mm00710307 m1),
IL-10 (Mm00439614 m1), IL-1𝛽 (Mm00434228 m1),
CCL2 (Mm00441242 m1), CCL5 (Mm01302427 m1), TGF𝛽
(Mm03024053 m1), collagen I𝛼1 (Mm00801666 g1), collagen
I𝛼3 (Mm01254476 m1), Lox (Mm00495386 m1), MMP2
(Mm00439498 m1), MMP9 (Mm00442991 m1), TIMP1
(Mm00441818 m1), TIMP2 (Mm004418225 m1), actin,
alpha 1, skeletal muscle, ACTA, (Mm00808218 g1), Atrial
Natriuretic Peptide, and ANP (Mm01255747 g1). Gene
expression was determined as fold induction over uninjured
hearts after normalising to the reference gene, GAPDH.
2.8. Statistics. Data are presented as mean ± SEM. Two-
tailed Student’s t-test was performed to compare WT and
𝛼MHC.IGF-1Ea mice at selected time points after MI. Data
were analysedwithGraphPad-Prism 5.0 (Graphpad Software,
Inc., www.graphpad.com), and differences were considered
statistically significant at 𝑃 < 0.05.
3. Results
3.1. IGF-1Ea Improves Cardiac Function after Myocardial
Infarction. Endogenous IGF-1Ea expression in WT hearts
was measured 1, 3, 5, 7, and 28 days after MI in both ischemic
and remote (nonischemic) regions. IGF-1Ea levels increased
in both the ischemic and remote regions (Figure 1(a)) with a
substantially stronger induction in the ischemic area (8-fold
over uninjured levels). These results indicate that, similar to
other organs, endogenous IGF1-Ea expression is upregulated
after cardiac tissue damage [23, 24]. In 𝛼MHC.IGF-1Ea
hearts, the baseline expression of transgenic IGF-1Ea was
much higher than the expression of endogenous IGF-1Ea
in WT hearts (average 286-fold) at all experimental time
points (Supplementary 1A and 1B). Although far exceeding
the expression of endogenous IGF-1Ea, the 𝛼MHC.IGF-
1Ea transgenic mice provide a suitable model of IGF-1Ea
at supraphysiological concentrations of possible therapeutic
relevance.
Previously our group showed an improvement in cardiac
function in 𝛼MHC.IGF-1Ea compared to WT mice one
month after MI [25]. To pinpoint the start of functional
improvement we extended this analysis and performed
echocardiography before and 1, 3, 5, 7, and 28 days after MI
(Supplementary Table 1). One day followingMI, both groups
displayed a reduction in ejection fraction (EF); however,
𝛼MHC.IGF-1Ea hearts showed significant improvement in
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Figure 1: 𝛼MHC.IGF-1Ea improves cardiac function and reduces dilation as early as 7 days after myocardial infarction. (a) Levels of IGF-1Ea
in the ischemic and in the remote area ofWT hearts at 1, 3, 5, 7, and 28 days followingMI. (b) Left ventricular ejection fraction (LVEF) and (c)
left ventricular end systolic volume (LVESV) after MI. Solid lines represent WTmice. Dashed lines represent 𝛼MHC.IGF-1Ea mice. Levels of
(d) actin-alpha 1 skeletal muscle (ACTA 1) and (e) atrial natriuretic peptide (ANP) mRNA expression 28 days after MI. Results are expressed
as mean fold induction ± SEM over the values of uninjured hearts. 𝑛 = 4–6 per group. Two-tailed Student’s t-test was performed to compare
WT versus 𝛼MHC.IGF-1Ea at selected time points after MI. ∗𝑃 < 0.05, ∗∗𝑃 < 0.005.
left ventricular EF by day 7 after MI (Figure 1(b) and Sup-
plementary Table 1). Left ventricular end systolic/diastolic
volumes significantly increased after MI in WT hearts,
indicating left ventricular dilation, while the 𝛼MHC.IGF-
1Ea hearts did not display any such signs (Figure 1(c) and
Supplementary Table 1). In support of the functional data,
the expression of molecular markers for cardiac damage such
as actin-alpha 1 skeletal muscle (ACTA) and atrial natriuretic
peptide (ANP) was significantly reduced in 𝛼MHC.IGF-1Ea
compared to WT mice 28 days after MI (Figures 1(d) and
1(e)).The peak of endogenous IGF-1Ea in the ischemic region
of WT mice by day 7, along with the improvement in cardiac
function in 𝛼MHC.IGF-1Ea as early as day 7, indicates that
IGF-1Ea signalling at early time points is key for cardiac
repair.
3.2. Altered Tissue Remodelling in𝛼MHC.IGF-1Ea after Injury.
Three days after MI, WT and 𝛼MHC.IGF-1Ea hearts dis-
played infarcts of equal size, quantified byMasson’s trichrome
staining (Figure 2(a)). However, by 28 days after infarction,
𝛼MHC.IGF-1Ea hearts exhibited smaller scar areas compared
to WT (Figures 2(b), 2(c) and 2(d)), as previously reported
[25]. This was observed as a reduction in scar length but
increased scar thickness, consistent with reduced infarct
expansion. As amolecular measurement of fibrosis, we quan-
tified TGF-𝛽 mRNA levels which were significantly lower
in 𝛼MHC.IGF-1Ea than in WT mice after MI (Figure 2(e)).
We therefore measured expression of genes involved in ECM
turnover and synthesis, MMP-2, MMP-9, TIMP-1, TIMP-2,
Col I𝛼1, Col I𝛼3, and lysyl oxidase (Lox) at 1, 3, 5, 7, and
28 days after MI. In WT hearts, MMP-9 was upregulated
3 days after MI, followed by MMP-2 at day 7 (Figures 2(f)
and 2(g)). Interestingly, neither MMP-2 nor MMP-9 was
significantly upregulated in 𝛼MHC.IGF-1Ea hearts at any
time point. Inhibitors of matrix degradation, TIMP-1 and
TIMP-2, had similar expression in WT and 𝛼MHC.IGF-1Ea
hearts at all time points except for day 7 when TIMP-2 was
significantly upregulated in𝛼MHC.IGF-1Ea hearts compared
to WT (Figures 2(h) and 2(i)). Taken together, this supports
the idea of a net overall reduction in matrix breakdown,
which may contribute to the reduced fibrosis observed in
𝛼MHC.IGF-1Ea hearts.
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Figure 2: Positive remodeling in the 𝛼MHC.IGF-1Ea infarcted region after myocardial infarction. Quantification of the infarcted area at (a)
3 days and (b) 28 days after MI. 𝑛 = 3. Representative histological sections of (c) WT and (d) 𝛼MHC.IGF-1Ea hearts stained with Masson’s
trichrome 28 days after MI. Scale bar: 1mm. ((e)–(l)) mRNA relative expression of (e) transforming growth factor beta (TGF-𝛽), (f) matrix
metalloproteinase 9 (MMP-9), (g) matrix metalloproteinase 2 (MMP-2), (h) tissue inhibitor of metalloproteinase (TIMP) 2, (i) TIMP-1, (j)
collagen (Col) I𝛼1, (k) Col I𝛼3, (l) ColI𝛼1/ColI𝛼3 ratio, (m) lysyl oxidase in the infarct area. Results are expressed as mean fold induction ±
SEM. Solid lines representWTmice. Dashed lines represent 𝛼MHC.IGF-1Eamice. 𝑛 = 3 per group. Two-tailed Student’s t-test was performed
to compare WT versus 𝛼MHC.IGF-1Ea at selected time points after MI. ∗𝑃 < 0.05, ∗∗𝑃 < 0.005, ∗∗∗𝑃 < 0.001.
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We next analysed the composition of the newly synthe-
sised matrix by measuring mRNA expression of the most
abundant cardiac ECM collagen, Col I𝛼1 and Col I𝛼3, as
well as the collagen cross-linker, lox, which increases matrix
stiffness. Upregulation of both collagen types was detected
by day 3, peaking at day 7 (Figures 2(j) and 2(k)). At this
time point, WT hearts expressed significantly more of both
collagen types than 𝛼MHC.IGF-1Ea hearts. We also noted a
difference in the ratio of the two collagen types; 𝛼MHC.IGF-
1Ea hearts had a reduced Col I𝛼1/Col I𝛼3 ratio compared to
WT, which was significant at days 3, 7, and 28 (Figure 2(l)). At
the peak of collagen upregulation, lox was also upregulated
in WT hearts, yet this was not observed in 𝛼MHC.IGF-
1Ea hearts (Figure 2(m)). These results indicate that IGF-1Ea
overexpression reduces ECM turnover afterMI and alters the
composition of thematrix, with preferential expression of Col
I𝛼3 over Col I𝛼1 and less cross-linking, which likely alters the
mechanical properties of the fibrotic area.
3.3. Distinct Chemokine and Cytokine Production in 𝛼MHC-
IGF-1Ea Hearts after Myocardial Infarct. Tissue remodelling
after injury is closely tied to the inflammatory process.
We therefore compared the inflammatory status of the
𝛼MHC.IGF-1Ea and WT hearts, monitoring the production
of key immune genes IL-1𝛽, IL-10, MCP-1, and CCL5.
Expression of the inflammatory cytokine IL-1𝛽 was rapidly
induced upon injury in WT hearts (66-fold over uninjured)
yet was not upregulated as strongly in 𝛼MHC.IGF-1Ea hearts
(19-fold over uninjured; Figure 3(a)). Similarly the strong
upregulation of MCP-1 in WT hearts was not observed in
𝛼MHC.IGF-1Ea hearts (Figure 3(b)). IL-10 was also rapidly
upregulated, peaking 1 day after MI. In contrast to IL-1𝛽
and MCP-1, this immunosuppressive cytokine was upreg-
ulated 3-fold higher in 𝛼MHC.IGF-1Ea hearts compared
to WT controls. Although a second peak of IL-10 mRNA
at 7 days was comparable in both WT and 𝛼MHC.IGF-
1Ea hearts 7 days after MI (Figure 3(c)). CCL5, which is
involved in the recruitment of Ly6Clow monocytes [26, 27],
was upregulated in 𝛼MHC.IGF-1Ea hearts 7 days after MI
(Figure 3(d)). These data suggest an early bias towards a
less inflammatory environment potentially modulating the
recruitment of monocytes in 𝛼MHC.IGF-1Ea hearts after
myocardial infraction.
3.4. IGF-1Ea Modulates Myeloid Cell Recruitment after Myo-
cardial Infarction. To document accumulation of the main
innate immune cell populations involved in cardiac inflam-
mation after infarct, single cell suspensions were prepared
fromwholemouse hearts and analysed by flow cytometry. All
cell populations described in this work were identified using
the gating strategy shown in Supplementary Figures 3–6.
In WT and 𝛼MHC.IGF-1Ea hearts, the total number
of infiltrating leukocytes (CD45+) gradually increased after
MI, both reaching comparable peak numbers at day 5
(Figure 4(a)). However at the earlier 3-day time point,
𝛼MHC.IGF-1Ea hearts contained 49% less leukocytes per
milligram of tissue than WT hearts. In examining spe-
cific immune cell populations, this difference was partly
explained by a 75% reduction in neutrophils (CD45+,
CD11b+, F4/80−, CD11c−, and Ly6G+; 186 versus 46 cells/mg
of tissue, Figure 4(b)) and a 67% reduction in monocytes
(CD45+, CD11b+, CD11c−, Ly6G−, and F4/80−; 191 versus 62
cells/mg of heart, Figure 4(c)); however it was mostly due to
reduced presence of macrophages (CD45+, CD11b+, CD11c−,
Ly6G−, and F4/80+; 58%, 2276 versus 949 cells/mg of heart,
Figure 4(f)). These data agree with the reduced MCP-1
expression observed in 𝛼MHC.IGF-1Ea hearts (Figure 3(b)),
as it is the principal chemokine involved in monocyte
recruitment [26, 28].
The Ly6C surface marker distinguishes two different
subsets ofmonocytes [2, 3]. Analysis of the Ly6Chigh (CD45+,
CD11b+, CD11c−, Ly6G−, F4/80−, and Ly6Chigh) and Ly6Clow
(CD45+, CD11b+, CD11c−, Ly6G−, F4/80−, and Ly6Clow)
populations revealed that the reduction of total monocyte
numbers at day 3 was attributable to a 20% decrease of the
Ly6Chigh population (102 versus 32 cells/mgof heart), whereas
the Ly6Clow population was not significantly different in WT
compared to 𝛼MHC.IGF-1Ea (Figures 4(d) and 4(e)) hearts.
To differentiate between inflammatory and reparative
macrophage populations, we used the markers Ly6C and
CD206. For this work, only cells that were either Ly6C+/
CD206− or Ly6C−/CD206+ were analysed, although we
noted a double positive cell population (i.e., CD206+,
Ly6C+). However no changes were observed over time
between WT and 𝛼MHC.IGF-1Ea for the double positive
population (Supplementary 2). Both Ly6C+ inflammato-
ry macrophage (CD45+, CD11b+, CD11c−, Ly6G−, F4/80+,
and Ly6C+/CD206−) and CD206+ reparative macro-
phage (CD45+, CD11b+, CD11c−, Ly6G−, F4/80+, and
Ly6C−/CD206+) normalised cell numbers were reduced by
71% and 48%, respectively, in 𝛼MHC.IGF-1Ea hearts at the
day 3 time point (522 versus 153 and 596 versus 310 cells/mg
of tissue of heart, resp.; Figures 4(g) and 4(h)); however
this was significant only for the Ly6C+ population. By day 7
after MI, macrophage dynamics changed and we observed
a greater number of total macrophages in 𝛼MHC.IGF-1Ea
hearts compared to WT, which was mainly due to a 155%
preferential increase in the CD206+ population (575 versus
1468 cells/mg heart, Figure 4(h)). Dendritic cells (CD45+,
CD11b+, F4/80−, CD11c+, and Ly6G−) were increased by
48% in 𝛼MHC.IGF-1Ea hearts compared to WT 5 days after
MI (168 versus 248 cells/mg heart; Figure 4(i)).
In summary, cardiac-restricted expression of an IGF-1Ea
transgene limited the early accumulation of innate immune
cells at day 3 after MI, with a bias towards the reduction of
inflammatory myeloid populations rather than regenerative
populations. This reduction corresponds with the lower
expression of myeloid chemokines and the less inflammatory
milieu observed in the 𝛼MHC.IGF-1Ea hearts.
4. Discussion
Previous work in our lab showed that local expression of IGF-
1Ea promoted functional restoration after MI and observed
reduced infarct expansion, thinning, and dilation of the left
ventricular wall [25]. We now demonstrate transcriptional
modulation of key ECM remodelling genes in the IGF-
1Ea hearts associated with tempering of the inflammatory
myeloid cell response.
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Figure 3: Cytokine dynamics in the infarcted 𝛼MHC.IGF-1Ea hearts. (a) Interleukin- (IL-) 1𝛽, (b) MCP-1, (c) IL-10, (d) CCL5 at several time
points after permanent ligation. Solid lines represent WT mice. Dashed lines represent 𝛼MHC.IGF-1Ea mice. Results are expressed as mean
fold induction ± SEM over the values of uninjured hearts. 𝑛 = 3 per group. Two-tailed Student’s t-test was performed to compare WT versus
𝛼MHC.IGF-1Ea at selected time points after MI. ∗𝑃 < 0.05, ∗∗𝑃 < 0.005.
Increased MMP expression after injury has been impli-
cated in contributing to scar destabilisation, as transgenic ani-
mal model knockouts of either MMP-2 or MMP-9 have been
shown to attenuate LV dilation, rupture, and impairment of
cardiac function [29, 30]. While MMP-2 and MMP-9 mRNA
expression levels were upregulated in injured WT hearts,
this increase was not observed in 𝛼MHC.IGF-1Ea hearts. In
line with reduced matrix breakdown, mRNA expression of
the MMP inhibitor, TIMP-2, was significantly increased in
𝛼MHC.IGF-1Ea hearts at day 7 after MI. Thus IGF-1Ea may
prevent adverse cardiac remodelling, in part, by modulating
transcription of MMPs/TIMPs.
The production of new matrix components was also
altered by the presence of the IGF-1Ea transgenewith an over-
all reduction in collagen synthesis, confirmed in histological
stains, and a bias towards expression of Col I𝛼3 over Col
I𝛼1. In MI patients, turnover of cardiac extracellular matrix
can be assessed by using circulating collagen peptides as
blood biomarkers [31] and high type I collagen is associated
with adverse clinical outcome [32]. A prospectivemulticentre
study further showed that a low type III/type I collagen ratio
especially at 1 month after MI is predictive of detrimental
left ventricular remodelling as well as cardiovascular deaths
and hospitalisation cases for heart failure [33]. Changes in
collagen ratios are known to affect the strength and tensile
properties of the ECM. It would be interesting to determine
whether these properties are modified in the 𝛼MHC.IGF-1Ea
hearts.
IGF-1Ea could promote the changes in collagen depo-
sition by directly acting on fibroblasts as it promotes both
their proliferation and activation to myofibroblasts [34,
35]. Alternatively, IGF-1Ea may influence accumulation and
activation of immune cells present at the infarct which in
turn regulate myofibroblast activation. Indeed, we observed
modulation of the inflammatory process in 𝛼MHC.IGF-
1Ea hearts, with less monocyte (Ly6Chigh) infiltration into
the injured myocardium. This effect is associated with
reduced expression of themonocyte chemoattractantMCP-1,
although no significant changes were observed in the Ly6Clow
monocyte population in infarcted hearts, possibly due to
CCL5 upregulation.
It is interesting that while complete depletion of mono-
cytes at any stage of repair leads to poor recovery [36],
a more subtle modulation of the monocyte population in
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Figure 4: Characterisation and temporal dynamics of immune cell populations in 𝛼MHC.IGF-1Ea hearts after MI. Quantification of (a) total
leukocytes (CD45+), (b) neutrophils (CD45+, CD11b+, F4/80−, CD11c−, and Ly6G+), and (c) monocytes (CD45+, CD11b+, CD11c−, Ly6G−,
and F4/80−) which were further classified as (d) Ly6Chigh and (e) Ly6Clow monocytes. (f) Macrophages (CD45+, CD11b+, CD11c−, Ly6G−,
and F4/80+) were further characterised on the basis of Ly6C and CD206 expression as (g) Ly6Chigh/CD206low (inflammatory macrophages)
and (h) Ly6Clow/CD206high (reparative macrophages). For this work, only cells that were either Ly6Chigh/CD206− or Ly6C−/CD206+ were
analysed, although we noted a double positive cell population (i.e., CD206+, Ly6C+). (i) Dendritic cells were defined as CD45+, CD11b+,
F4/80−, CD11c+, and Ly6G−. Data is presented as the total number of cells per mg of heart. 𝑛 = 4–6 per group. Two-tailed Student’s t-test
was performed to compare WT versus 𝛼MHC.IGF-1Ea at selected time points after MI. ∗𝑃 < 0.05, ∗∗𝑃 < 0.005.
the 𝛼MHC.IGF-1Ea hearts is associated with improved heart
function. Studies abrogating monocyte recruitment using
a selective CCR2 inhibitor have resulted in reduced IL-
1𝛽, IL-6, MCP-1, and TNF𝛼 levels [37]. IGF-1Ea influ-
ences macrophage polarisation in skeletal muscle [38]
and we similarly found reduced Ly6Chigh monocyte and
Ly6C+ macrophage normalised cell numbers while CD206+
macrophage numbers were increased by day 7, suggesting
that IGF-1Ea promoted a quick progression to the reparative
phase of repair by modulating macrophage phenotype. In
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the 𝛼MHC.IGF-1Ea hearts we observed a decrease in MCP-1,
which is the chemokine for CCR2, recently shown to distin-
guish infiltrating monocytes from the resident macrophage
population which has a different embryological origin and
expresses CD206 [39–41]. It is therefore possible that, in our
𝛼MHC.IGF-1Ea transgenic mouse model, IGF-1Ea reduces
the infiltration of inflammatory Ly6Chigh monocytes by
preventing upregulation of MCP-1 while still allowing for
expansion of the resident macrophage population.
In summary, we show that the 𝛼MHC.IGF-1Ea mouse
model can modulate several associated aspects of the cellular
repair process after MI, including immune cell recruit-
ment, cytokine expression, and matrix turnover. All of these
changes occur within the first 7 days after infarct, at which
time a functional improvement can already be measured in
𝛼MHC.IGF-1Ea hearts compared toWT controls.These data
provide new insights into the mechanism of IGF-1Ea and
suggest that early immunomodulation is key to successful
cardiac repair after injury.
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